BioCentury | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor delta (PPARδ)

...survival compared with vehicle. Next steps could include testing PPARδ agonists in other HD models. Kalypsys Inc....
BioCentury | May 10, 2012
Distillery Therapeutics

Indication: Hepatic disease

...a Phase II trial of KD3010 to treat liver fibrosis in HCV nonresponders. KD3010 from Kalypsys Inc....
BioCentury | May 10, 2012
Targets & Mechanisms

PPAR's new course

...KD3010 and GW501516-as well as an undisclosed PPARg (PPARG) agonist. KD3010 is being developed by Kalypsys Inc....
...in their liver-twice." Launching the study also could be problematic, as it is unclear whether Kalypsys...
...S.A. , Labege, France Genfit S.A. (Euronext:ALGFT), Lille, France GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Kalypsys Inc....
BioCentury | Aug 3, 2010
Company News

Aragon names Heyman CEO

...president and head of R&D. Prior to co-founding the cancer company, Heyman was CSO at Kalypsys Inc....
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Neurology

...the iNOS inhibitor compound 274150 in Phase II testing for rheumatoid arthritis (RA) and asthma. Kalypsys Inc....
...published online April 17, 2009; doi:10.1021/jm900173b Contact: Nicholas D. Smith, Kalypsys Inc., San Diego, Calif. e-mail: nsmith@kalypsys.com BC...
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Neurology

...the iNOS inhibitor compound 274150 in Phase II testing for rheumatoid arthritis (RA) and asthma. Kalypsys Inc....
...published online April 17, 2009; doi:10.1021/jm900173b Contact: Nicholas D. Smith, Kalypsys Inc., San Diego, Calif. e-mail: nsmith@kalypsys.com BC...
BioCentury | Feb 26, 2009
Distillery Therapeutics

Indication: Inflammation

...GlaxoSmithKline plc, is in Phase II testing to treat RA. KD7040, an iNOS inhibitor from Kalypsys Inc....
BioCentury | Nov 24, 2008
Product Development

PPAR delta pipeline

...Type IIb dyslipidemia Ph II Cerenis CER-002 Second generation PPAR delta agonist Atherosclerosis Ph I Kalypsys...
BioCentury | Mar 10, 2008
Company News

Numira board of directors update

...Inc. , Irvine, Calif. Business: Supply/Service Appointed: Paul Grint, CMO and head of development at Kalypsys Inc. WIR...
BioCentury | Dec 24, 2007
Clinical News

KD7040: Phase IIa started

...KD7040 vs. placebo for 14 days in 50 PHN patients with moderate to severe pain. Kalypsys Inc....
Items per page:
1 - 10 of 54
BioCentury | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor delta (PPARδ)

...survival compared with vehicle. Next steps could include testing PPARδ agonists in other HD models. Kalypsys Inc....
BioCentury | May 10, 2012
Distillery Therapeutics

Indication: Hepatic disease

...a Phase II trial of KD3010 to treat liver fibrosis in HCV nonresponders. KD3010 from Kalypsys Inc....
BioCentury | May 10, 2012
Targets & Mechanisms

PPAR's new course

...KD3010 and GW501516-as well as an undisclosed PPARg (PPARG) agonist. KD3010 is being developed by Kalypsys Inc....
...in their liver-twice." Launching the study also could be problematic, as it is unclear whether Kalypsys...
...S.A. , Labege, France Genfit S.A. (Euronext:ALGFT), Lille, France GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Kalypsys Inc....
BioCentury | Aug 3, 2010
Company News

Aragon names Heyman CEO

...president and head of R&D. Prior to co-founding the cancer company, Heyman was CSO at Kalypsys Inc....
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Neurology

...the iNOS inhibitor compound 274150 in Phase II testing for rheumatoid arthritis (RA) and asthma. Kalypsys Inc....
...published online April 17, 2009; doi:10.1021/jm900173b Contact: Nicholas D. Smith, Kalypsys Inc., San Diego, Calif. e-mail: nsmith@kalypsys.com BC...
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Neurology

...the iNOS inhibitor compound 274150 in Phase II testing for rheumatoid arthritis (RA) and asthma. Kalypsys Inc....
...published online April 17, 2009; doi:10.1021/jm900173b Contact: Nicholas D. Smith, Kalypsys Inc., San Diego, Calif. e-mail: nsmith@kalypsys.com BC...
BioCentury | Feb 26, 2009
Distillery Therapeutics

Indication: Inflammation

...GlaxoSmithKline plc, is in Phase II testing to treat RA. KD7040, an iNOS inhibitor from Kalypsys Inc....
BioCentury | Nov 24, 2008
Product Development

PPAR delta pipeline

...Type IIb dyslipidemia Ph II Cerenis CER-002 Second generation PPAR delta agonist Atherosclerosis Ph I Kalypsys...
BioCentury | Mar 10, 2008
Company News

Numira board of directors update

...Inc. , Irvine, Calif. Business: Supply/Service Appointed: Paul Grint, CMO and head of development at Kalypsys Inc. WIR...
BioCentury | Dec 24, 2007
Clinical News

KD7040: Phase IIa started

...KD7040 vs. placebo for 14 days in 50 PHN patients with moderate to severe pain. Kalypsys Inc....
Items per page:
1 - 10 of 54